Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice? ; volume:10 ; number:5 ; day:10 ; month:7 ; year:2019 ; pages:1625-1643 ; date:10.2019
Diabetes therapy ; 10, Heft 5 (10.7.2019), 1625-1643, 10.2019
- Urheber
-
Deed, Gary
Atherton, John J.
d’Emden, Michael
Rasalam, Roy
Sharma, Anita
Sindone, Andrew
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-019-0663-x
- URN
-
urn:nbn:de:101:1-2020021310463856926645
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Deed, Gary
- Atherton, John J.
- d’Emden, Michael
- Rasalam, Roy
- Sharma, Anita
- Sindone, Andrew
- SpringerLink (Online service)
Ähnliche Objekte (12)
Updates on cardiovascular outcome trials in diabetes
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Perspectives in Managing Kidney Disease and Atherosclerotic Cardiovascular Disease
Adaptive designs for clinical trials in cardiovascular diseases
Current perspectives on cardiovascular outcome trials in diabetes
Patients’ experiences managing cardiovascular disease and risk factors in prison
Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials
Managing clinical trials
Correction to: Updates on cardiovascular outcome trials in diabetes
PDM-ProValue meets cardiovascular outcome trials in diabetes
Cardiovascular outcome trials of glucose-lowering medications: an update
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
Updates on cardiovascular outcome trials in diabetes
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Perspectives in Managing Kidney Disease and Atherosclerotic Cardiovascular Disease
Adaptive designs for clinical trials in cardiovascular diseases
Current perspectives on cardiovascular outcome trials in diabetes
Patients’ experiences managing cardiovascular disease and risk factors in prison
Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials
Managing clinical trials
Correction to: Updates on cardiovascular outcome trials in diabetes
PDM-ProValue meets cardiovascular outcome trials in diabetes
Cardiovascular outcome trials of glucose-lowering medications: an update
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
Updates on cardiovascular outcome trials in diabetes
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Perspectives in Managing Kidney Disease and Atherosclerotic Cardiovascular Disease
Adaptive designs for clinical trials in cardiovascular diseases
Current perspectives on cardiovascular outcome trials in diabetes
Patients’ experiences managing cardiovascular disease and risk factors in prison
Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials
Managing clinical trials
Correction to: Updates on cardiovascular outcome trials in diabetes
PDM-ProValue meets cardiovascular outcome trials in diabetes
Cardiovascular outcome trials of glucose-lowering medications: an update